Type 2 Diabetes - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Type 2 Diabetes - Pipeline Review, H1 2018’, provides an overview of the Type 2 Diabetes pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Type 2 Diabetes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes

- The report reviews pipeline therapeutics for Type 2 Diabetes by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Type 2 Diabetes therapeutics and enlists all their major and minor projects

- The report assesses Type 2 Diabetes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Type 2 Diabetes

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adocia SAS

Aegis Therapeutics LLC

AFFiRiS AG

Akcea Therapeutics Inc

Allist Shanghai Pharmaceutical Technology Co Ltd

Amarantus Bioscience Holdings Inc

Amgen Inc

Aphios Corp

Arecor ...

Adocia SAS

Aegis Therapeutics LLC

AFFiRiS AG

Akcea Therapeutics Inc

Allist Shanghai Pharmaceutical Technology Co Ltd

Amarantus Bioscience Holdings Inc

Amgen Inc

Aphios Corp

Arecor Ltd

Arena Pharmaceuticals Inc

AstraZeneca Plc

AusBio Ltd

Avadel Pharmaceuticals Plc

Bayer AG

Betagenon AB

Betta Pharmaceuticals Co Ltd

Biocon Ltd

BioLingus AG

BioRestorative Therapies Inc

Biozeus

Biscayne Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Boston Therapeutics Inc

Braasch Biotech LLC

Bristol-Myers Squibb Co

C4X Discovery Holdings PLC

Cadila Healthcare Ltd

Cadila Pharmaceuticals Ltd

Caelus Health

Cardax Inc

Carmot Therapeutics Inc

Cellix Bio Pvt Ltd

Celon Pharma SA

Center Laboratories Inc

Chipscreen Biosciences Ltd

Chong Kun Dang Pharmaceutical Corp

Cinnagen Co

CJ HealthCare Corp

CohBar Inc

Concenter BioPharma Silkim Ltd

CymaBay Therapeutics Inc

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Dance Biopharm Inc

Delpor Inc

Diabetology (Products) Ltd

Diamyd Medical AB

Diasome Pharmaceuticals Inc

DiscoveryBiomed Inc

DNJ Pharma Inc

Dong-A Socio Holdings Co Ltd

Elcelyx Therapeutics Inc

Eli Lilly and Co

Eloxx Pharmaceuticals Inc

Energenesis Biomedical Co Ltd

Enteris BioPharma Inc

Enzene Biosciences Ltd

Enzo Biochem Inc

Epichem Pty Ltd

Eternygen GmbH

Evotec AG

F. Hoffmann-La Roche Ltd

Generex Biotechnology Corp

Genexine Inc

Genfit SA

Genmedica Therapeutics SL

Genovate Biotechnology Co LTD

Geropharm LLC

Gilead Sciences Inc

GlaxoSmithKline Plc

Glucox Biotech AB

Hanmi Pharmaceuticals Co Ltd

Heptares Therapeutics Ltd

HitGen LTD

Hyundai Pharmaceutical Co Ltd

Immupharma Plc

Immuron Ltd

Inflazome Ltd

Innovative Targeting Solutions Inc

Inspyr Therapeutics Inc

InStar Technologies AS

Intarcia Therapeutics Inc

Intas Pharmaceuticals Ltd

Integral Molecular Inc

Intercept Pharmaceuticals Inc

Intrexon Corp

Ionis Pharmaceuticals Inc

Japan Tobacco Inc

Jeil Pharmaceutical Co Ltd

JHL Biotech Inc

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Kadimastem Ltd

Kadmon Corp LLC

Kissei Pharmaceutical Co Ltd

Kowa Co Ltd

Laboratorios Silanes SA de CV

Lead Discovery Center GmbH

Leading BioSciences Inc

Lexicon Pharmaceuticals Inc

LG Chem Ltd

LipimetiX Development Inc

Longevity Biotech Inc

Luye Pharma Group Ltd

Magnus Life Ltd

MannKind Corp

Medesis Pharma SA

MedImmune LLC

Medlab Clinical Ltd

Merck & Co Inc

Mesoblast Ltd

Metabolic Solutions Development Company LLC

Metabolys SAS

Metacrine Inc

Mitsubishi Chemical Holdings Corp

Mitsubishi Tanabe Pharma Corp

Naia Ltd

Neurimmune Holding AG

NGM Biopharmaceuticals Inc

Novapeutics LLC

Novartis AG

NovaTarg Therapeutics Inc

Novo Nordisk AS

Omeros Corp

OPKO Biologics Ltd

OPKO Health Inc

Oramed Pharmaceuticals Inc

Original BioMedicals Co Ltd

Palatin Technologies Inc

Panacea Biotec Ltd

Paras Biopharmaceuticals Finland Oy

Peptron Inc

Pfizer Inc

PharmaCyte Biotech Inc

PharmaIN Corp

Pila Pharma AB

Poxel SA

Prometheon Pharma LLC

ProMetic Life Sciences Inc

Prothena Corp Plc

Purzer Pharmaceutical Co Ltd

Reata Pharmaceuticals Inc

reMYND NV

Renova Therapeutics Inc

Reset Therapeutics Inc

Rezolute Inc

Saniona AB

Sanofi

Sanwa Kagaku Kenkyusho Co Ltd

SATT Conectus Alsace SAS

SBI Pharmaceuticals Co Ltd

ScandiCure AB

Seres Therapeutics Inc

Serodus ASA

Serometrix LLC

Shenzhen HighTide Biopharmaceutical Ltd

Shionogi & Co Ltd

Sirona Biochem Corp

SJT Molecular Research SL

SK Chemicals Co Ltd

Sprint Bioscience AB

Sumitomo Dainippon Pharma Co Ltd

Suzuken Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Co Ltd

Teijin Pharma Ltd

The Medicines Company

Theracos Inc

Thermalin Diabetes LLC

Tiziana Life Sciences Plc

Toray Industries Inc

Torrent Pharmaceuticals Ltd

Transgene Biotek Ltd

TTY Biopharm Company Ltd

Twoxar Inc

Uni-Bio Science Group Ltd

ViaCyte Inc

Vichem Chemie Research Ltd

Vicore Pharma AB

Viking Therapeutics Inc

Vivus Inc

vTv Therapeutics Inc

Vybion Inc

XBiotech Inc

XERIS Pharmaceuticals Inc

XL-protein GmbH

XOMA Corp

XuanZhu Pharma Co Ltd

Yabao Pharmaceutical Group Co Ltd

Yuhan Corp

Zafgen Inc

Zealand Pharma AS

Table of Contents

Table of Contents

Table of Contents 2

Introduction 11

Type2 diabetes – Overview 12

Type2 diabetes – Therapeutics Development 13

Type2 diabetes – Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 11

Type2 diabetes – Overview 12

Type2 diabetes – Therapeutics Development 13

Type2 diabetes – Therapeutics Assessment 67

Type2 diabetes – Companies Involved in Therapeutics Development 88

Type2 diabetes – Drug Profiles 177

Type2 diabetes – Dormant Projects 996

Type2 diabetes – Discontinued Products 1035

Type2 diabetes – Product Development Milestones 1045

Appendix 1055

List of Tables

List of Tables

Number of Products under Development for Type2 diabetes, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Tables

Number of Products under Development for Type2 diabetes, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Type2 diabetes – Pipeline by Adocia SAS, H1 2018

Type2 diabetes – Pipeline by Aegis Therapeutics LLC, H1 2018

Type2 diabetes – Pipeline by AFFiRiS AG, H1 2018

Type2 diabetes – Pipeline by Akcea Therapeutics Inc, H1 2018

Type2 diabetes – Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018

Type2 diabetes – Pipeline by Amarantus Bioscience Holdings Inc, H1 2018

Type2 diabetes – Pipeline by Amgen Inc, H1 2018

Type2 diabetes – Pipeline by Aphios Corp, H1 2018

Type2 diabetes – Pipeline by Arecor Ltd, H1 2018

Type2 diabetes – Pipeline by Arena Pharmaceuticals Inc, H1 2018

Type2 diabetes – Pipeline by AstraZeneca Plc, H1 2018

Type2 diabetes – Pipeline by AusBio Ltd, H1 2018

Type2 diabetes – Pipeline by Avadel Pharmaceuticals Plc, H1 2018

Type2 diabetes – Pipeline by Bayer AG, H1 2018

Type2 diabetes – Pipeline by Betagenon AB, H1 2018

Type2 diabetes – Pipeline by Betta Pharmaceuticals Co Ltd, H1 2018

Type2 diabetes – Pipeline by Biocon Ltd, H1 2018

Type2 diabetes – Pipeline by BioLingus AG, H1 2018

Type2 diabetes – Pipeline by BioRestorative Therapies Inc, H1 2018

Type2 diabetes – Pipeline by Biozeus, H1 2018

Type2 diabetes – Pipeline by Biscayne Pharmaceuticals Inc, H1 2018

Type2 diabetes – Pipeline by Boehringer Ingelheim GmbH, H1 2018

Type2 diabetes – Pipeline by Boston Therapeutics Inc, H1 2018

Type2 diabetes – Pipeline by Braasch Biotech LLC, H1 2018

Type2 diabetes – Pipeline by Bristol-Myers Squibb Co, H1 2018

Type2 diabetes – Pipeline by C4X Discovery Holdings PLC, H1 2018

Type2 diabetes – Pipeline by Cadila Healthcare Ltd, H1 2018

Type2 diabetes – Pipeline by Cadila Pharmaceuticals Ltd, H1 2018

Type2 diabetes – Pipeline by Caelus Health, H1 2018

Type2 diabetes – Pipeline by Cardax Inc, H1 2018

Type2 diabetes – Pipeline by Carmot Therapeutics Inc, H1 2018

Type2 diabetes – Pipeline by Cellix Bio Pvt Ltd, H1 2018

Type2 diabetes – Pipeline by Celon Pharma SA, H1 2018

Type2 diabetes – Pipeline by Center Laboratories Inc, H1 2018

Type2 diabetes – Pipeline by Chipscreen Biosciences Ltd, H1 2018

Type2 diabetes – Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018

Type2 diabetes – Pipeline by Cinnagen Co, H1 2018

Type2 diabetes – Pipeline by CJ HealthCare Corp, H1 2018

Type2 diabetes – Pipeline by CohBar Inc, H1 2018

Type2 diabetes – Pipeline by Concenter BioPharma Silkim Ltd, H1 2018

Type2 diabetes – Pipeline by CymaBay Therapeutics Inc, H1 2018

Type2 diabetes – Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018

Type2 diabetes – Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Type2 diabetes – Pipeline by Dance Biopharm Inc, H1 2018

Type2 diabetes – Pipeline by Delpor Inc, H1 2018

Type2 diabetes – Pipeline by Diabetology (Products) Ltd, H1 2018

Type2 diabetes – Pipeline by Diamyd Medical AB, H1 2018

Type2 diabetes – Pipeline by Diasome Pharmaceuticals Inc, H1 2018

Type2 diabetes – Pipeline by DiscoveryBiomed Inc, H1 2018

Type2 diabetes – Pipeline by DNJ Pharma Inc, H1 2018

Type2 diabetes – Pipeline by Dong-A Socio Holdings Co Ltd, H1 2018

Type2 diabetes – Pipeline by Elcelyx Therapeutics Inc, H1 2018

Type2 diabetes – Pipeline by Eli Lilly and Co, H1 2018

Type2 diabetes – Pipeline by Eloxx Pharmaceuticals Inc, H1 2018

Type2 diabetes – Pipeline by Energenesis Biomedical Co Ltd, H1 2018

Type2 diabetes – Pipeline by Enteris BioPharma Inc, H1 2018

Type2 diabetes – Pipeline by Enzene Biosciences Ltd, H1 2018

Type2 diabetes – Pipeline by Enzo Biochem Inc, H1 2018

Type2 diabetes – Pipeline by Epichem Pty Ltd, H1 2018

Type2 diabetes – Pipeline by Eternygen GmbH, H1 2018

Type2 diabetes – Pipeline by Evotec AG, H1 2018

List of Figures

List of Figures

Number of Products under Development for Type2 diabetes, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Figures

Number of Products under Development for Type2 diabetes, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports